Aegle Therapeutics Appoints Industry Veteran Dr. Scott Braunstein As Chairman Of The Board

Aegle Therapeutics, a clinical-stage biopharmaceutical company focused on dermatology and the development of innovative treatments for rare and severe skin diseases, has announced the appointment of Dr. Scott Braunstein as Chairman of the Board. Dr. Braunstein brings extensive leadership experience and clinical insight to Aegle at a pivotal time in the company’s development. 

He will provide strategic guidance as Aegle advances its lead product candidate, AGLE-102, through early-stage clinical trials. AGLE-102 is a novel therapy composed of mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) and is currently being studied in a Phase 1/2a clinical trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). RDEB is a rare and debilitating genetic disorder that primarily affects children, causing fragile skin that blisters and tears easily.

Shelley Hartman, CEO of Aegle, stated, “We are excited to welcome Dr. Braunstein as Chairman and look forward to his guidance as we advance the development of AGLE-102 as a novel therapeutic platform for rare and severe dermatological disorders. Dr. Braunstein’s extensive industry experience will be a valuable addition to our leadership team as we continue to develop AGLE-102 for RDEB and other subtypes of epidermolysis bullosa.”

Dr. Braunstein noted, “Aegle is at the forefront of advancing extracellular vesicle-based therapies which have exciting potential across a broad spectrum of refractory dermatological disorders. I look forward to working with Shelley and the management team to advance their current mission of offering patients and their families a novel and simple biological solution for the treatment of EB.”

Dr. Braunstein’s background in both clinical medicine and biopharmaceutical leadership positions him well to support Aegle’s mission. His experience will be instrumental in helping the company navigate the complexities of clinical development in rare dermatological diseases and in shaping the long-term vision for AGLE-102 and other potential therapies in Aegle’s pipeline. The appointment marks an important step for Aegle Therapeutics as it continues to progress its first-in-class approach to treating underserved patient populations with significant unmet medical needs.